NK cells are primary effectors of antibody-dependent cellular cytotoxicity (ADCC), a key mechanism of action of several therapeutic monoclonal antibodies (mAbs) that function, in part, by directing NK cell cytotoxic activity to tumor targets.19 The potent NK cell activating receptor CD16 (FCGR3A) triggers ADCC on binding the constant region (Fc) of antibody-coated target cells.19 Combining adoptive NK cell infusions with mAb treatment represents one promising combination strategy that aims to augment the capacity of NK cells to mediate ADCC.15 16. This evidence concerns the gene FCGR3A and neoplasm.